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Previous findings in liver transplantation patients 
have raised the concept that HLA plays a dualistic role. 
HLA matching will reduce rejection but may augment 
MHC restricted cellular immune mechanisms of liver 
allograft injury. To evaluate this concept. we studied 
CMV heplt.:itis in 399 FK506-treated liver transplant 
patients, including 355 cases for which complete HLA-
A,B,DR.DQ typing information was available. CMV 
hepatitis developed in 25 patients, and 17 of them (or 
68%) showed a one or two HLA-DR antigen match with 
the donor. In contrast. HLA-DR matches were found in 
only 35% of 330 patients without CMV hepatitis 
(P=0.005). No significant associations were seen for 
HLA-A. HLA-B. and RLA-DQ antigens. In pretrans-
plant CMV -seronegative patients with seropositive 
grafts (n=39). the frequency of CMV hepatitis was 44% 
for HLA-DR-matched livers but 14% for HLA-DR-un-
matched livers. In seropositive recipients (n= 187). these 
frequencies were 12% and 2% for HLA-DR-matched and 
unmatched liver grafts. Chronic rejection developed in 
29 patients (or 8%) during a follow-up between 10 and 
24 months after transplantation. Its incidence was 
higher in the CMV hepatitis group (24% vs. 6%) 
(P=O.007). Although no associations were found be-
tween HLA matching and the incidence of chronic rejec-
tion, there was an earlier onset of chronic rejection of 
HLA-DR-matched livers irrespective of CMV hepatitis. 
These findings suggest that an HLA-DR match be-
tween donor and recipient increases the incidence of 
CMV hepatitis in both primary and secondary CMV 
infections. Although HLA compatibility leads to less 
acute cellular rejection. it is suggested that DR matching 
may accelerate chronic rejection of liver transplants. 
perhaps through HLA-DR-restricted immunological 
mechanisms toward viral antigens. including CMV. 
Liver allografts matched for HLA. especially HLA-DR, have 
lower survival rates, not only in cyclosporine-treated patients 
(1.2) but also in patients on FK506 immunosuppression (3), 
Since H LA mismatching contributes to liver allograft rejection. 
we have proposed a dualistic role of HLA in liver transplanta-
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tion (1), HLA compatibility will reduce rejection but may 
augment other cellular immune mechanisms of liver allograft 
injury. especially those mediated by major histocompatibility 
complex-restricted lymphocytes, These mechanisms could be 
related to immune responses to viral infections and underlying 
autoimmune disease. 
Cytomegalo\'irus hepatitis in liver transplant recipients has 
offered an opponunitv to im'estigate the dualistic role of HLA. 
C'.IV -specitic immune mechanisms are believed to he the pri-
mary mediators of liver allograft injury during CMV infection 
(-/). Several in vitro studies have demonstrated MHC-restricted 
lymphocyte responsiveness to CMV (5-11). According to the 
MHC restriction concept, CMV antigen presentation by "self' 
HLA antigens will augment CMV -specific cellular immunity 
and cell-mediated injury. HLA matching of CMV -infected 
transplants patients will permit CMV antigen presentation by 
"self' HLA antigens. and this would promote T cell mediated 
effector mechanisms of allograft damage, In this report we 
present evidence that an HLA-DR compatibility is associated 
with more CMV hepatitis in liver transplant patients. 
A significant complication of CMV infection is chronic rejec-
tion. Higher frequencies of graft coronarY arterv disease have 
been reported for c~nD . infected heart ~ranspiant recipients 
112.13). In lung transplant patients. CMV infection is associ-
ated with bronchiolitis obliterans due to chronic rejection (14. 
15). In vitro proliferation assays have demonstrated a persist-
ence of primed CMV -specific lymphocytes in hronchoalveolar 
lavages several months after symptomatic CMV infection, and 
this is associated with a high incidence of subsequent bronchio-
litis obliterans (16). Kidney transplant patients with CMV 
infection experience more rejection. and no differences have 
been noted in survivals of HLA-matched and mismatched 
kidney transplants (17. 18), Moreover. a higher incidence of 
CMV infection has been reported for patients with HLA-DR-
matched kidney transplants ( 18, 19). This suggests that CMV 
infection can override the beneticial effect of HLA matching 
on kidney transplant outcome. 
In liver transplant patients. CMV infection is associated with 
the development of the vanishing bile duct syndrome, a mani-
festation of chronic rejection (20). The incidence of vanishing 
bile duct syndrome appears to be higher for liver transplants 
from donors with HLA-DR matches (2). The studies described 
in this report show an association between chronic rejection 
and CMV hepatitis and also that HLA-DR matching acceler-
ates the development of chronic rejection in liver transplant 
recipients. 
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MATERIALS AND METHODS 
Study population and immunosuppression. This study was conducted 
on 399 adult patients who underwent orthotopic liver transplantation 
at the University of Pittsburgh between August 1989 and December 
1990 and who had survived for at least 3 months after surgery. Liver 
allograft biopsies were performed when clinically indicated by an ele-
vation of liver function tests. changes in the color or quantity of bile 
production. or by any clinical suspicion of graft dysfunction. 
Al! patients received FK506 as the primary immunosuppressive 
agent. The protocol of FK506 treatment is described elsewhere (21 \. 
Briefly, FK506 was initially given in a continuous infusion at 0.1 mg/ 
kg/day, which was converted to an oral dose of 0.15 mg/kg every 12 hr 
with the return of bowel function. Subsequent dosage adjustments were 
guided by the quality of the graft, the presence of rejection. toxicity. 
p.nd FK506 plasma trough level (normal value: <2 ng/m]). Rejection 
episodes were treated with a 1 g bolus of methylprednisolone or a 
"recycling" of high-dose steroids starting at 200 mg and tapering to 20 
mg over five days. Steroid· resistant rejection episodes were treated 
with a 5·day course of OKT3. 
Serology. Complete donor-recipient HLA typing was done for 355 
liver transplant cases. HLA·A,B t\-ping was done by standard Amos-
modified lymphocytotoxicity assays with local and commercial typing 
trays. HLA·DR,DQ typing was done by two·color fluorescence. Pre-
transplant CMV serological status of donor and recipient was available 
for 262 transplant cases. 
Dwgnosis of CMV hepatitis. This study focused on CMV hepatitis 
rather than CMV infection of liver transplant patients. The diagnosis 
of CMV hepatitis was based on ty-pical inclusion bodies or direct 
immunoperoxidase detection of CMV early antigen in a liver specimen 
obtained by (percutaneous) liver biopsy. 
Diagnosis of chronic rejection. Histological criteria for chronic rejec-
tion are described elsewhere (22) and include lymphocytic bile duct 
damage in 50% or more of the portal triads. with evidence of bile duct 
loss and hepatocanalicular cholestasis. 
Statistical anolvsis. Associations between HLA matching and CMV 
hepatitis and chronic rejection were assessed by Chl·square analysis. 
Odds ratios were calculated for the estimation of the relative risks. The 
\1ann Whitney 1..' nonparametric test· was used to analyze differences 
in the time of onset of chronic rejection between groups. 
RESULTS 
CMV hepatitis developed in 25 of 355 liver transplant pa-
tients 17";: I: the median time of diag-nosis was 33.5 days after 
transplantation (range: 13-278 days). The incidence of CMV 
hepatItis was significantly higher for HLA·DR-compatible liver 
transplants (Table 1), Seventeen of the 25 CMV hepatitis 
patients 168':0) shared at least one HLA-DR antigen with the 
donor (Table 11. In contrast. HLA-DR sharing was found in 
123 of 330 patients 135':0) without CMV hepatitis I P=O.OOS). 
An HLA-DR match increased the relative risk of CMV HLA 
by a factor of 3.6. There seemed no preferential sharing of any 
particular HLA-DR antigen in the CMV hepatitis group. Also. 
the incidence of other symptomatic C~ls infections appeared 
unaffected by HLA-DR sharing. There were no differences 
TABLE 1. Association between CMV hepatitis and HLA matching in 
liver transplantation 
Frequency of HLA·matched 
Donor with liver transplants Relative pi~nificance Mlitch eMV hepatitis :-';0 eMV hep- risk" 
fn=~~1 atitis I n=:n()I 
For HLA-A -10% 37% P=NS 
For HLA·B We 24% P=NS 
For HLA-DR 68"'C 35% P=O.OO5 3.6 
For HLA·DQ ~Dl"" 1- ( 64% P=NS 
a Relative risk of CMV hepatitis in matched versus unmatched liver 
transplants. 
between DR matched and unmatched hepatitis patients in 
terms of severity of liver dysfunction and responsiveness to 
gancic10vir therapy. 
No significant associations were found between CMV hepa-
titis and donor-recipient sharing of HLA-A. HLA-B, and HLA-
DQ antigens (Table 1), In this group of FKS06-treated patients, 
a similar incidence of CMV hepatitis was seen in patients who 
received OKT3 (4/57 or 7%) and those without OKT3 treat-
ment (21/298 or 7%). 
Pretransplant CMV serological status was known for 262 
HLA-DR-typed donor-recipient pairs (Table 2). Thirty-nine of 
the CMV -seronegative patients received CMV -seropositive 
grafts and 11 patients (28%) developed CMV hepatitis. In this 
group, the incidence of CMV hepatitis was about three times 
higher in livers with a shared HLA-DR antigen than in HLA-
DR unmatched grafts (44% vs. 14%) (P=0.07). Of the other 36 
seronegative recipients. only 3 (8%) who received livers from 
seronegative donors developed CMV hepatitis. Only one had 
HLA-DR sharing. 
CMV hepatitis was observed in 1~ (5<;0) of 187 pretransplant 
seropositive patients. and 8 of these cases involved an HLA-
DR match. Table 2 shows that in this group the frequency of 
hepatitis due to secondary CMV infection was 12% in HLA-
DR-matched livers but only 2% in the HLA-DR-unmatchecj 
liver transplants (P=0.006)' These data suggest that HLA-DR 
sharing between recipient and donor increases the risk for both 
primary and secondary C:v1V hepatitis after liver transplanta-
tion. 
During a follow-up of between 10 and 24 months after trans-
plantation. 29 patients 18%) developed chronic rejection. The 
incidence of chronic rejection was four-fold higher in the CMV 
hepatitis group (24 C;,) than in patients without CMV hepatitis 
16':0: P<O.OOS) lTable :3j). Moreover. chronic rejection occurred 
sooner in the C:\I\, hepatitis group. The median post transplant 
time of onset was 60 days (range: 4a-.')Ol days) in the CMV 
hepatitis group and 245 days (range: :15-660 days) in patients 
without CMV hepatitis (P=0.07). Five of the I patients (or 
TABLE 2. Incidence of primary and secondary C\1V hepatitis in HLA-DR-matched and HLA-DR·unmatched liver transplants 
Pretransplant C!VIV status 
Recipient -, Donor> 
Recipient .. Donor> or -. 
Recipient-, Donor-
n 
18 
69 
15 
HLA·DR·matched 
I"'er transplants 
EI~fyD hep811t1S 
-44% 
12% 
" Relative risk of CMY hepatitis for HLA·DR matching. 
• In this grouP. 110 donors were CMV+ and 77 donors were CMV-. 
n 
21 
118 
21 
HLA·DR·unmatchM 
liver transplants 
eMV hepat1l1s 
1-1% 
2% 
10% 
Significance 
P=O.07 
P=0.006 
NS 
Relative 
risk" 
4.8 
7.6 
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71 %) with chronic rejection preceded by CMV hepatitis shared 
HLA-DR with the liver transplant donor. 
In the overall group of liver transplant patients. we did not 
find significant differences in the incidence of chronic rejection 
of liver transplants matched or mismatched for HLA-A.B,DR 
or DQ (Table 3). However, HLA-DR sharing was associated 
with an earlier onset of chronic rejection in patients irrespective 
of CMV hepatitis status (Fig. 1). The median onset of chronic 
rejection was 130 days (range: 35-284 days) for livers with an 
HLA-DR match and 356 days (range: 43-660 days) for HLA-
DR-unmatched livers (P<O.Ol). Thus. HLA-DR matching ap-
pears to accelerate the development of chronic rejection after 
liver transplantation. 
afpClippfl~ 
These observations suggest that HLA-DR sharing between 
donor and recipient promotes the development of CMV hepa-
titis in liver transplant patients. They are consistent with the 
concept of a dualistic role of HLA that predicts that HLA 
compatibility decreases graft rejection but may augment other 
cellular immune mechanisms of transplant injury. especially 
those mediated by MHC-restricted lymphocytes (1). CMV dis-
~ase appears to be mediated by cellular immune reactivity (4), 
and several in"vitro studies have demonstrated HLA restricted 
TABLE 3. Associations of chronic rejection with CMY hepatitis and 
HLA matching of liver transplants 
Chronic ~o 
Allograft status rejection chronic Significance 
rejection In=29) In=3261 
CMV hepatitis 24% 6'1 P=O.OOO7 
HLA-A match 28% 38% :\'S 
HLA-B match 10% 25% :-;8 
HLA-DR match 45% 39% NS 
HLA-DQ match 82% 66% NS 
700 
c: 
.5:! 600 
U P 
G> 
Gi 
a: 500 
~ 
c: 
~ 400 1::. 
U 
"0 
~ 300 8 
III 
c: 0 0 
"0 200 oe 
• >-
-+-... 
Cl 100 
.. 
'?11 
0 
HLA-OA Matched 
(N. I 3} 
• Pal,enlS w,Ih CMV hepal,I,s 
o PalleniS Without CMV hepat't's 
lymphocyte reactivity toward CMV (5-11). The present data 
suggest that HLA-DR antigen sharing between donor and 
recipient leads to higher incidence of CMV hepatitis in liver 
transplant patients. No association of CMV hepatitis with 
HLA-A, HLA-B. and HLA-DQ sharing was observed. 
The incidence of CMV hepatitis was lower in this group of 
FK506-treated patients (7%) than that reported from our cen-
ter in cyclosporine-treated liver transplant recipients (12%) 
(25). Similarly, the incidence and severity of enteric CMV 
infection was less in FK506-treated than in cyclosporine-
treated patients (26). 
In cyclosporine-treated patients OKT3 therapy is associated 
with a higher incidence of CMV infection (23). Whereas pa-
tients on FK506 require less 0 KT3 therapy (2 I ). it also appears 
that in FK506-treated patients. OKT3 does not promote CMV 
enteritis (26)-or. as shown in this study. the development of 
CMV hepatitis. Because the pathogenesis of CMV infection is 
thought to involve cell-mediated immune mechanisms. it is 
possible that this lower incidence of CMV infection is related 
to the immunosuppressive efficacy of FK506. Whatever the 
explanation. HLA-DR-matched liver transplants in FK506-
treated patients are at increased risk for hepatitis caused by 
primary and secondary CMV infection. HLA·DR matching 
status seems germane in the consideration of CMV prophylaxis 
after liver transplantation. 
Although structural similarities have been reported between 
CMV and HLA gene sequences (27-29), the most likely expla-
nation for the increased incidence of CMV hepatitis in HLA-
DR-matched transplanted livers is the phenomenon of MHC 
restriction of antigen-specific lymphocyte reactivity. CMV in-
fection of a transplanted liver leads to the expression of CMV-
derived antigens-which, in context with MHC molecules on 
the cell surface. are presented by infected cells recognized bv 
recipient T lymphocytes. Both class 1(5,6) and class II (8-11-) 
HLA-restricted CMV -specific T cell responses have been re-
ported. HLA matching will permit MHC-restricted antigen 
0 
< 0.01 0 
B 
oe 
~ 
0 
8> 
0 
0 
• 
HLA·OA Unmatched 
.N . ~ ~ \ 
FIGURE 1. Accelerated onset of chronic rejection in HLA-DR-matched liver transplants. 
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presentation, thereby augmenting cell-mediated immune re-
sponses toward CMV -infected liver allografts. 
This study did not reveal significant associations between 
CMV hepatitis and liver transplant matching for class I anti-
gens encoded hy the HLA-A and HLA-B loci. In vitro studies 
of human and murine lymphocytes have demonstrated class I 
MHC-reRtricted and CD8-positive CMV-specific cytotoxic T 
cells (5. 6 . .'){)l. These cells are believed to playa major role in 
the development of protective immunity to CMV infection (i. 
30). Conversely, class II MHC-restricted C~s-specific T cells 
generally have the CD4 phenotype and can be expected to 
produce lymphokines that mediate inflammatory processes 
leading to hepatic injury. Such lymphokines could augment 
cellular rejection mechanisms. For instance. C~s -activated T 
cells could release interleukin-2 which causes expansion of 
graft-infiltrating alloreactive lymphocytes, and interferon-
gamma, which furt her upregulates the expression of HLA an-
tigens on target cells. Recent studies in lung transplant patients 
have demonstrated that the persistence of proliferative CMV-
specific lymphocytes in bronchoalveolar lavages correlates with 
increased donor alloreactivity within the lung allograft (16). 
CMV infection also increases the risk of chronic rejection of 
lung allografts ( 15 l. 
This study has also shown a higher incidence of chronic 
rejection in liver transplant recipients who experienced CMV 
hepatitis. O'Grady et al. (20) have reported an association 
between CMV infection and the vanishing bile duct syndrome 
in liver transplant patients, and that HLA-DR matching of the 
liver donor represented an additional risk factor. These inves-
tigators concluded that HLA-DR status is not a predisposing 
factor for CMV infection. Our data suggest, instead, that HLA-
DR matching increases the risk of CMV hepatitis. which then 
leads to a higher incidence of chronic rejection. 
We have found that HLA-DR matching is associated with 
an earlier onset, but not a higher frequency, of chronic rejection_ 
Since this HLA-DR matching effect was also seen in patients 
without C':\1V hepatitis, it seems that additional HLA-DR-
restricten l~Dmphoc:-;te responses to as-yet-undefined antigens 
rna\' contrihute to accelerated chronic rejection of the li\'er 
allograft. aonald~on et al. '2) haVl' proposed a mechanism of 
HLA-DR-restricted T cell response to class I HLA antIgens to 
explain the higher risk of vanishing bile duct syndrome. This 
mechanism requires the generation of peptides from endoge-
nous class I HLA molecules that would be presented by class 
II HLA molecules on the surface of the bile duct epithelium of 
the donor li\"t>r. At present. we are unaware of experimental 
suppOrt ll/ t hIS model. :YloreoVl'r. class I HLA antigens are 
readil~D secreted 11\' the transplanted liver (31), and it seems 
pOSSIble that sllch soluble antigens are taken up and processed 
primarily h~D am igen-presenting cells of the recipient. There-
fore. we believe t hat the accelerated chronic rejection of an 
HLA-DR-matched liver transplant is more likely related to 
HLA-DR-restricted immune responses during viral infection. 
and perhaps even autoimmune disease. 
In summary. the findings descrihed in this report expand the 
concept of the dualistic role of HLA in liver transplantation 
and help explain why survival is poorer with better matches. 
Although HLA-DR matching reduces acute cellular rejection, 
it is apparent that HLA-DR matching will not only increase 
the risk of CM\' hepatitis but also accelerate chronic rejection. 
A better understanding of the different HLA-associated im-
mune mechanisms within the liver allograft may lead to im-
proved management strategies in hepatic transplantation. 
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FACTORS ASSOCIATED WITH SEVERE INTRACRANIAL 
HYPERTENSION IN CANDIDATES FOR EMERGENCY LIVER 
TRANSPLANTATION! 
SANTIAGO J. MUNOZ,2 MICHAEL J. MORITZ,3 RODNEY BELL,· BRUCE NORTHRUP,5 PAUL MARTIN,6 
JOHN RADOMSKI3 
Departments of Medicine, Surgery, Neurology, and Neurosurgery, Jefferson Medical College, Philadelphia, Pennsylvania 19107 
Cerebral edema is the leading cause of death in pa-
tients with fulminant hepatic failure (FHF). Emergency 
OLT is often a life-saving therapy for FHF but severe 
cerebral edema is a contraindication to transplantation. 
We attempted to identify clinical and biochemical fac-
tors associated with the development of severe intracra-
nial hypertension in FHF. Fever, psychomotor agitation, 
and arterial hypertension were more frequently ob-
served preceding episodes of severe intracranial hyper-
tension, and more than 50% of FHF patients with un-
controlled intracranial hypertension sustained severe 
brain injury in our series. These observations suggest 
that vigorous treatment of fever, arterial hypertension, 
and agitation are important aspects of the intensive care 
1 Presented at the 11 th Annual Meeting of the American Society of 
Transplant Physicians, May 26-27, !992, Chicago,IL. 
2 Address correspondence to: Santiago J. Munoz, M.D., Division of 
Gastroenterology, Department of Medicine, Room 480, Main Building, 
132 S. 10th St., Philadelphia, PA 19107. 
3 Department of S\lJ'Pry. 
• Department of Neurology. 
6 Department of NeuJ'OIU1'gery. 
• Department of Medicine. 
management of FHF patients to maintain their OLT 
candidacy, 
Fulminant hepatic failure (FHF)* is an uncommon yet dra-
matic disorder characterized by development of hepatic en-
cephalopathy in the setting of acute liver injury. Patients with 
FHF have a mortality ranging from 50 to greater than 80%, 
and progress in intensive care techniques over the last decade 
has had little influence on the outcome of FHF (1-5). Cerebral 
edema leading to brainstem herniation is one of the most 
common causes of death in FHF patients but the mechanisms 
of cerebral edema in FHF are not fully understood (6-9). A 
lack of early and reliable neurological signs of brain swelling 
has led to an increasing use of devices for intracranial pressure 
monitoring in FHF patients (5, 7, 10-17). The successful intro-
duction of emergency OLT as a definitive therapy for FHF in 
1987 has since been verified in many centers, and OLT has 
represented a breakthrough in the management of patients 
with FHF (2-5). However, use of OLT is not appropriate in 
FHF patients who have developed. severe and irreversible brain 
injury due to cerebral herniation. We investigated clinical and 
• Abbreviation: FHF, fulminant hepatic failure. 
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